1. Home
  2. Nation
  3. Bharat Biotech claims ‘Covaxin’ effective against coronavirus strains found in India, UK

Bharat Biotech claims ‘Covaxin’ effective against coronavirus strains found in India, UK

By Saima Siddiqui 
Updated Date
Bharat Biotech claims ‘Covaxin’ effective against coronavirus strains found in India, UK

New Delhi: Manufacturer of COVID-19 vaccine, Covaxin, on Sunday claimed to have produced neutralising titres (concentration) against all key emerging variants tested, including the B.1.617 and B.1.1.7, first identified in India and the United Kingdom.

Also Read :- India reports 67,208 new cases, 2,330 deaths in last 24 hrs

A modest reduction in neutralisation by a factor of 1.95 was observed against the B.1.617 variant compared to the vaccine variant (D614G), said Bharat Biotech.

Link to article published in CID – Oxford University Press.
COVAXIN neutralising emerging variants. https://t.co/ZholzoDD7F pic.twitter.com/ksiNL1kLXq

— suchitra ella (@SuchitraElla) May 16, 2021

Also Read :- Bharat Biotech rebuffs controversy, says no calf serum in final 'Covaxin' dose

Bharat Biotech joint managing director Suchitra Ella cited a study published in peer-reviewed medical journal Clinical Infectious Diseases.

It, however, added that despite this reduction, neutralizing titre levels with B.!.617 remain above levels expected to be protective.

“No difference in neutralization between B.1.1.7 (first found in the UK) and vaccine strain (D614G) was observed,” Bharat Biotech added.

These findings are from a study conducted in collaboration with the National Institute of Virology – India Council of Medical Research.

It is to be mentioned that, Covaxin is one of the three Covid-19 vaccines that are currently available in the country.

Also Read :- PM to launch 'Customised Crash Course' for COVID-19 frontline workers

As per the Union Health Ministry, a total of 18,22,20,164 doses of Covid-19 vaccines have been administered across the country so far.

Further reading:
For the latest news and reviews, follow us on Facebook and Twitter ...
X